Image source: Pixabay.com

Highlights

  • EBOS Group is a diversified Australasian wholesaler, marketer and distributor of medical, pharmaceutical and healthcare products
  • In 1HFY24, revenue of EBO went up by 7.1% YoY to AUD 6.6 billion and underlying profit after tax increased by 7.6% YoY to AUD 152.4 million
  • Sybos Holdings Pte. Ltd. Has highest stake in EBO with a shareholding of nearly 18.70%

EBOS Group Limited (ASX: EBO) is an ASX-listed wholesaler, marketer, and distributor of medical, healthcare and pharmaceutical products. The company also owns, markets, and distributes an Australasian animal care brand.

In the first half of the financial year 2024 (1HFY24), EBO’s revenue surged by almost 7.1% YoY to AUD 6.6 billion, underlying EBITDA jumped 8.3% YoY to AUD 313.2 million and underlying profit after tax increased by 7.6% YoY to AUD 152.4 million.

The company announced a 7.5% YoY surge in its interim dividend on the back of healthy performance in 1HFY24.

During January 2024, the company witnessed positive trading conditions with  increase in underlying EBITDA, with and without the Chemist warehouse contract.

Top 10 shareholders of EBO

The top 10 shareholders of EBO have around 33.19% shareholding in the firm, while top four have nearly 27.09% of the shareholding. Sybos Holdings Pte. Ltd. and Capital Research Global Investors have the maximum stakes in the firm with a shareholding of ~18.70% and ~3.76%, respectively.

Recent business update

Through an ASX update dated 4 June 2024, the company informed about the appointment of Andrew McLean as the chief executive officer (CEO) for Medical Technology, effective 5 August 2024. With this development, the existing CEO for Medical Technology, Matt Muscio will be transitioning to the position of non-executive director, beginning 1 January 2025. Further, the company informed that peter Williams will retire as a director after the 2024 annual general meeting.

Outlook

In FY24, the company expects to see organic earnings growth in animal care and healthcare segments, and capital expenditure is expected to rise, compared to FY23.

The focus is on growth investments, modernising facilities, expanding into new segments, pursuing strategic acquisitions to strengthen core businesses and explore related adjacencies in animal care and healthcare.

Share performance of EBO

EBO shares closed 0.817% lower at AUD 30.330 apiece on 12 June 2024 with a market cap of AUD 5.90 billion. In the last one year, EBO’s share price has increased by7.25%, while in the last three months, it has decreased by 12.09%.

The 52-week high of EBO is AUD 35.800, recorded on 31 July 2023and 52-week low is AUD 30.180, recorded on 3 June 2024.

EBO Daily Technical Chart, Source: REFINITIV

Note 1: Past performance is neither an Indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, and currency, is 12 June 2024. The reference data in this report has been partly sourced from REFINITIV.